Patents by Inventor Gisela Schwab

Gisela Schwab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Liquid Dosage Forms to Treat Cancer
    Publication number: 20230301978
    Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
    Type: Application
    Filed: October 28, 2022
    Publication date: September 28, 2023
    Inventors: Khalid Shah, Gisela Schwab, Steven Lacy
  • COMBINATIONS FOR THE TREATMENT OF CANCER
    Publication number: 20230301979
    Abstract: The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of the free base of Compound 1, as well as crystalline forms of salts of Compound 1, in combination with a checkpoint inhibitor. The invention also relates to pharmaceutical compositions comprising these combinations. The invention further relates to methods of treating cancer by administering Compound 1 as a single agent or a combination described herein.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 28, 2023
    Inventors: Gisela Schwab, Christian Scheffold, Colin Chong, Ssucheng Jeff Hsu, Peter Lamb, Peiwen Yu
  • Method of Treating Cancer and Bone Cancer Pain
    Publication number: 20230149384
    Abstract: This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
    Type: Application
    Filed: October 13, 2022
    Publication date: May 18, 2023
    Inventors: Gisela Schwab, Dana T. Aftab
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20230045783
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: September 7, 2021
    Publication date: February 9, 2023
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20220401433
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: August 15, 2022
    Publication date: December 22, 2022
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Liquid dosage forms to treat cancer
    Patent number: 11504362
    Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 22, 2022
    Assignee: Exelixis, Inc.
    Inventors: Khalid Shah, Gisela Schwab, Steven Lacy
  • Method of treating cancer and bone cancer pain
    Patent number: 11504363
    Abstract: This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: November 22, 2022
    Assignee: Exelixis, Inc.
    Inventors: Gisela Schwab, Dana T. Aftab
  • Combinations of Cabozantinib and Atezolizumab to Treat Cancer
    Publication number: 20220056138
    Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Gisela Schwab, Christian Scheffold, Colin Hessel
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20220000857
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: September 7, 2021
    Publication date: January 6, 2022
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Combinations of cabozantinib and atezolizumab to treat cancer
    Patent number: 11198731
    Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: December 14, 2021
    Assignee: Exelixis, Inc.
    Inventors: Gisela Schwab, Christian Scheffold, Colin Hessel
  • Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Patent number: 11141413
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 12, 2021
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Liquid Dosage Forms to Treat Cancer
    Publication number: 20200268737
    Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
    Type: Application
    Filed: June 8, 2018
    Publication date: August 27, 2020
    Inventors: Khalid Shah, Gisela Schwab, Steven Lacy
  • Method of Treating Cancer and Bone Cancer Pain
    Publication number: 20200255382
    Abstract: This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
    Type: Application
    Filed: February 11, 2020
    Publication date: August 13, 2020
    Inventors: Gisela Schwab, Dana T. Aftab
  • Combinations of Cabozantinib and Atezolizumab to Treat Cancer
    Publication number: 20190352403
    Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
    Type: Application
    Filed: January 19, 2018
    Publication date: November 21, 2019
    Inventors: Gisela Schwab, Christian Scheffold, Colin Hessel
  • Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20190262330
    Abstract: The present disclosure relates to a method of treating liver cancer, particularly hepatocellular carcinoma, using cabozantinib, a kinase inhibitor.
    Type: Application
    Filed: December 21, 2018
    Publication date: August 29, 2019
    Inventors: Gisela Schwab, Ann E. Borgman, Colin Hessel
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20190209547
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: April 17, 2017
    Publication date: July 11, 2019
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Method of Treating Cancer and Bone Cancer Pain
    Publication number: 20140179736
    Abstract: This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
    Type: Application
    Filed: May 2, 2012
    Publication date: June 26, 2014
    Applicant: Exelixis, Inc.
    Inventors: Gisela Schwab, Dana T. Aftab
  • METHOD FOR PREDICTING RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-DIRECTED THERAPY
    Publication number: 20100279323
    Abstract: This invention provides methods for determining or predicting response to cancer therapy in an individual.
    Type: Application
    Filed: June 29, 2010
    Publication date: November 4, 2010
    Inventors: Sarah S. BACUS, David Haskett LYNCH, Pamela LOCKBAUM, Gisela SCHWAB, Xiao-dong YANG
  • Method for predicting response to epidermal growth factor receptor-directed therapy
    Patent number: 7771958
    Abstract: This invention provides methods for determining or predicting response to cancer therapy in an individual.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 10, 2010
    Assignee: Amgen Inc.
    Inventors: Sarah S. Bacus, David Haskett Lynch, Pamela Lockbaum, Gisela Schwab, Xiao-dong Yang
  • Method for Predicting Response to Epidermal Growth Factor Receptor-Directed Therapy
    Publication number: 20070134252
    Abstract: This invention provides methods for determining or predicting response to cancer therapy in an individual.
    Type: Application
    Filed: October 11, 2006
    Publication date: June 14, 2007
    Inventors: Sarah Bacus, David Lynch, Pamela Lockbaum, Gisela Schwab, Xiao-dong Yang